Gena Wang
Stock Analyst at Barclays
(2.43)
# 2,424
Out of 5,182 analysts
238
Total ratings
44.03%
Success rate
-0.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $87 → $95 | $64.59 | +47.08% | 7 | Apr 6, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $18.20 | +339.56% | 8 | Feb 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $23.91 | +109.12% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.84 | +235.37% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $51.28 | -51.25% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.83 | +1.23% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.26 | +281.83% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $70.85 | -4.02% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.23 | -10.03% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $446.78 | -7.34% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $8.10 | +11.11% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $9.89 | -9.00% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $321.28 | +64.03% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $76.43 | +24.30% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $56.30 | +42.10% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.52 | +127.27% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $42.36 | -59.87% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $8.96 | +312.95% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $51.72 | +8.28% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $26.33 | -20.24% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $9.83 | +215.36% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.89 | +3.81% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $27.35 | -67.09% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.22 | +204.14% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $9.34 | +92.72% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.80 | +15.38% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.12 | +5,271.09% | 1 | Jan 6, 2017 |
Cytokinetics
Apr 6, 2026
Maintains: Overweight
Price Target: $87 → $95
Current: $64.59
Upside: +47.08%
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $18.20
Upside: +339.56%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $23.91
Upside: +109.12%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.84
Upside: +235.37%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $51.28
Upside: -51.25%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.83
Upside: +1.23%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.26
Upside: +281.83%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $70.85
Upside: -4.02%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.23
Upside: -10.03%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $446.78
Upside: -7.34%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $8.10
Upside: +11.11%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $9.89
Upside: -9.00%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $321.28
Upside: +64.03%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $76.43
Upside: +24.30%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $56.30
Upside: +42.10%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.52
Upside: +127.27%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $42.36
Upside: -59.87%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $8.96
Upside: +312.95%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $51.72
Upside: +8.28%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $26.33
Upside: -20.24%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $9.83
Upside: +215.36%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.89
Upside: +3.81%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $27.35
Upside: -67.09%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.22
Upside: +204.14%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $9.34
Upside: +92.72%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.80
Upside: +15.38%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.12
Upside: +5,271.09%